Glioblastoma (GBM) is the most common malignant brain tumor in adults, responsible for
approximately 225,000 deaths per year. Despite preclinical successes, most interventions …

Glioblastoma multiforme (GBM) is a deadly CNS malignancy with an average survival of~ 12
months post diagnosis despite aggressive treatment. Immunotherapy approaches to treat …

2084 Background: Outcome for glioblastoma (GBM) remains dismal and innovative
treatment strategies are desperately needed. Growing data support the contribution of local …

Immune checkpoint inhibitors (CIs) have changed the landscape of tumor immunotherapy.
Glioblastoma (GBM) remains the most common primary malignant brain tumor in adults and …

Glioblastoma Multiforme (GBM) is a highly malignant primary brain cancer that is associated
with abysmal prognosis. The median survival of GBM patients is∼ 15 months and there …

Inhibition of immune checkpoints, including cytotoxic T-lymphocyte antigen-4 (CTLA-4),
programmed death-1 (PD-1), and its ligand PD-L1, has demonstrated exciting and durable …

Glioblastoma, the most common primary brain tumor in adults, is invariably fatal despite all
current therapies, with a median survival of about 15 months. Glioblastoma contains cancer …

Background Combined immunotherapy approaches are promising cancer treatments. We
evaluated anti–programmed cell death protein 1 (PD-1) treatment combined with gene …

The negative phase 3 trial of anti-PD-1 in human glioblastoma (GBM) contradicts preclinical
data showing eradication of GL261 mouse brain tumors by checkpoint inhibitors (CPI). To …

Immune checkpoint blockade (ICB) is currently evaluated in patients with glioblastoma
(GBM), based on encouraging clinical data in other cancers, and results from studies with …